Ionis Q4 2025: A Beat on the Bottom Line, But Guidance Resets the Expectation Gap

The numbers for Ionis's fourth quarter were a clear beat. Revenue came in at $203 million, a surprise of +30.48% over the Zacks Consensus Estimate of $155.58 million. Earnings per share also topped expectations, with a loss of -$1.14 compared to the consensus estimate of -$1.21. On the surface, this looks like a strong quarter where the company outperformed the whisper number.

Yet the market's reaction was muted, and the real story is the expectation gap that opened up. The strong quarter is now in the past. The critical context is what management just said about the future. For 2026, Ionis is guiding to revenue of $800–825 million. That implies a significant deceleration from the 2025 run-rate, which was $944 million. The guidance reset is the key event here.

The beat was real, but it was against a lower bar set by the prior year's decline. The market is now being asked to price in a new, slower growth narrative for 2026, one that factors in the absence of a large one-time license fee that inflated 2025 results. The strong quarter doesn't change that forward view. It simply sets up a contrast: a powerful finish to 2025 versus a reset path ahead.

Commercial Momentum: What's Priced In and What's New

The commercial beat was real, but it was largely expected. The market had already priced in strong execution on the launch of TRYNGOLZA. The drug hit $108 million in net sales for its first year, meeting the initial launch target and exceeding early market expectations. This success was a key driver of the 2025 revenue beat and is now in the rearview mirror. The real question is whether this execution is still a catalyst or simply the baseline for what's expected.

More interesting is the early promise of DAWNZERA. Management is estimating a peak sales potential in excess of $500 million. The early adoption signals are positive, with a reported 100% conversion to paid therapy from its free trial program. Yet, this high ceiling is not new information; it was part of the launch narrative. The market's focus has already shifted from the commercial potential of these two drugs to the next wave of catalysts.

That next wave is the pipeline. The key development here is the submission of a supplemental NDA for olezarsen in severe hypertriglyceridemia late in 2025. This is a major step toward a 2026 launch, which management is positioning as the company's first independent launch in a broad patient population. The Phase 3 data, showing up to a 72% triglyceride reduction, provides a strong clinical foundation. The expectation gap now lies in the execution of this launch and the subsequent launch of zilganersen for Alexander disease.

The bottom line is that the strong commercial results are likely already reflected in the stock. The beat on the bottom line was driven by these known commercial successes and a large one-time license fee. The reset guidance for 2026, which removes that fee, sets a lower bar for growth. The next potential surprise will come from the pipeline. If olezarsen and zilganersen launch on schedule and meet early adoption targets, they could close the expectation gap that guidance has opened. For now, the commercial momentum is priced in; the pipeline is the new variable.

The 2026 Guidance Reset: Sandbagging or Realism?

The 2026 outlook is the clearest signal yet of a reset expectation path. Management's guidance of $800–825 million in revenue implies a significant deceleration from the 2025 run-rate of $944 million. The math is straightforward: this range removes the one-time $280 million license fee that inflated last year's results. Stripping that out, the underlying growth target for 2026 is about 20%. This is not a case of management sandbagging for a soft quarter; it's a deliberate recalibration to a more sustainable, commercial-growth-based trajectory.

The guidance reset is paired with a stark reminder of the company's financial reality. Management expects a non-GAAP operating loss of $500–550 million for 2026. This massive loss underscores the continued heavy investment required to fund the pipeline and commercial launches. The market has priced in this burn, but the guidance makes it explicit for the coming year. It's a signal that profitability is not imminent, but the path to it is now being laid out.

Financially, the company is building a runway. Management projects a cash position of about $1.6 billion by year-end 2026, with a stated goal of achieving cash-flow breakeven by 2028. This sets a clear, multi-year timeline for the burn rate to reverse. The 2026 guidance, by removing the license fee and showing the continued operating loss, frames the next two years as a period of reinvestment and execution, not explosive top-line growth.

Viewed another way, this guidance is a form of expectation arbitrage. The market had already priced in the strong 2025 commercial beat and the pipeline potential. By guiding to a lower, more realistic growth path that excludes one-time items and includes a large operating loss, management is resetting the bar. The stock's muted reaction to the earnings print makes sense now: the beat was in the past, and the new forward view is one of steady, albeit costly, progress. The gap between the whisper number and the print has closed, replaced by a more grounded, but still ambitious, plan.

Catalysts and Risks: What to Watch for the Next Expectation Gap

The reset guidance has set a new baseline. Now, the stock's path hinges on whether near-term events can close the expectation gap that management has opened-or if they widen it. The next potential surprises are clear: the FDA's decision on olezarsen's priority review request by June 2026, the launch execution for zilganersen later in the year, and the risk that the 20% underlying growth target proves too optimistic.

The first major catalyst is the FDA's decision on olezarsen's supplemental NDA. Management has positioned this as the company's first independent launch in a broad patient population, with a planned launch-ready date of June pending the agency's timing. The Phase 3 data is strong, showing up to a 72% triglyceride reduction. A positive, timely decision would validate the pipeline's clinical promise and set the stage for a commercial beat. It would be the first real test of whether the new, slower growth narrative can still deliver a surprise.

The second critical event is the launch of zilganersen for Alexander disease later in 2026. This will be the first launch from Ionis's leading neurology pipeline and a key test of its commercial execution beyond the initial two launches. Success here is essential for validating the pipeline's broader potential and supporting the peak sales potential in excess of $500 million for DAWNZERA. Lagging adoption for either olezarsen or zilganersen would directly challenge the company's stated commitment to a ~20% underlying growth path.

The primary risk, therefore, is that commercial uptake for these new launches lags. The 20% growth target is already a step down from the 2025 run-rate. If early sales for olezarsen or zilganersen fall short of internal expectations, it could force another guidance reset, widening the expectation gap. The market has priced in steady progress; any deviation from that path would be met with skepticism.

The bottom line is that the next expectation gap will be defined by execution. The olezarsen FDA decision and the zilganersen launch are the near-term catalysts that could beat the reset bar. The risk is that commercial reality proves harder to achieve than the revised financial plan suggests. For now, the stock is trading on the new, more grounded narrative. The next earnings report will test whether that narrative holds.